HeartBeam Inc. (NASDAQ: BEAT) reported second-quarter 2026 financial and operational results, highlighting significant advancements in its heart attack detection program and initial commercial launch. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026. Additionally, HeartBeam surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study, a key step toward validating its technology for detecting heart attacks.
The company also announced the completion of a working prototype of its 12-lead ECG extended wear patch, a device designed to provide continuous monitoring over an extended period. HeartBeam has signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients, marking the beginning of its market presence.
Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, compared with a net loss of $5 million, or $0.15 per share, in the same period last year. As of June 30, 2026, the company held cash, cash equivalents, and restricted cash totaling $8.8 million. Management expects full-year 2026 net operating cash outflow to be below $14 million, which, combined with the current cash position, extends the company's cash runway into 2027.
These developments are crucial for HeartBeam as it seeks to commercialize its innovative 3D ECG technology, which has received FDA clearance for arrhythmia assessment and 12-lead ECG synthesis. The company's platform is designed to collect ECG signals from three non-coplanar directions, enabling the synthesis of a 12-lead ECG without cables, potentially revolutionizing cardiac care by allowing patients to monitor their heart health outside medical facilities.
The progress in the ALIGN-ACS and HEADSTART-ACS studies is particularly significant because these trials are designed to demonstrate the technology's ability to detect acute coronary syndrome (ACS) and heart attacks, which could lead to earlier diagnosis and treatment. The successful completion of these studies could pave the way for broader regulatory approvals and adoption in clinical practice.
HeartBeam's commercial agreements and initial shipments indicate that the company is transitioning from development to revenue generation, a critical milestone for any medical technology firm. The company's focus on four targeted U.S. geographies suggests a strategic approach to market entry, allowing for focused sales and marketing efforts.
Investors and stakeholders will be watching closely as HeartBeam continues to execute its plans. The upcoming presentation of ALIGN-ACS results at TCT 2026 will be a key catalyst, providing clinical evidence of the technology's performance. Additionally, the company's ability to manage its cash burn and extend its runway into 2027 provides financial stability to support its operations and research initiatives.
For more information, visit the company's newsroom at https://ibn.fm/BEAT and the full press release at https://ibn.fm/QjrtT.
